Phase II trial to evaluate the safety and efficacy of inhaled alpha-1 antitrypsin (AAT) in patients with cystic fibrosis.

Trial Profile

Phase II trial to evaluate the safety and efficacy of inhaled alpha-1 antitrypsin (AAT) in patients with cystic fibrosis.

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2014

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Kamada
  • Most Recent Events

    • 24 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top